Pharmafile Logo

Outcomes-based payment

- PMLiVE

J&J gets CHMP backing for broader Darzalex use

Recommendation for earlier-stage approval could see multiple myeloma drug reach blockbuster sales

- PMLiVE

Novartis’ Zykadia nears first-line lung cancer label

Hopes to boost slow second-line sales to compete directly with Pfizer’s Xalkori and Roche’s Alecensa 

- PMLiVE

FDA OKs Valeant’s psoriasis drug Siliq, with black box warning

Suicidal ideation labelling adds to challenge in rivalling Novartis’ Cosentyx and Lilly’s Taltz

- PMLiVE

Merck BACE inhibitor adds to litany of Alzheimer’s trial failures

Interim data shows “virtually no chance” of clinical success for verubecestat

- PMLiVE

Novartis signs ‘connected inhaler’ deal with Propeller Health

Will connect its Breezhaler devices to Propeller's digital platform

- PMLiVE

Trump talks pricing and manufacturing with pharma

Heads of Celgene, Lilly, Merck & Co, Novartis and trade body PhRMA met at the White House

- PMLiVE

Novartis talks the talk with new MS digital tools

Presents real world terms in online dictionary and Chrome Extension

Novartis Gehry Building

Novartis ‘reviewing options’ for Alcon division

Possible sale or spin-off in store for eyecare unit as firm reports Q4 operating loss of $132m

- PMLiVE

Real-world evidence

Companies are now recruiting high-level executives to lead well-resourced RWE teams as industry looks to reshape the future

Novartis building

Novartis takes biosimilar delay complaint to Supreme Court

Seeks to overturn US law that requires 180-day launch delay after regulatory approval

- PMLiVE

NICE U-turn on Novartis’ Afinitor for kidney cancer

Set to back treatment's routine NHS use following offer of discount and new data

Novartis building

Novartis boosts cardiovascular pipeline with $1bn Ionis deal

Gains rights to two lipoprotein-targeting drugs currently in early-stage clinical development 

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links